Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
You may also be interested in...
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: